BioAtla, Inc.
NASDAQ:BCAB
Overview | Financials
Company Name | BioAtla, Inc. |
Symbol | BCAB |
Currency | USD |
Price | 0.496 |
Market Cap | 28,803,461 |
Dividend Yield | 0% |
52-week-range | 0.425 - 4.02 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Jay M. Short Ph.D. |
Website | https://www.bioatla.com |
An error occurred while fetching data.
About BioAtla, Inc.
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD